Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
FORWARD I trial has completed full enrolloment; top-line results expected in the first half of 2019 WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that
View HTML
Toggle Summary ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee , Ph.D. has been appointed Executive Vice President and Chief Business Officer.
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 20, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab at the Society of Gynecologic Oncology Annual Meeting
WALTHAM, Mass.--( BUSINESS WIRE )-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in
View HTML
Toggle Summary ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 14, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming
View HTML
Toggle Summary ImmunoGen Reports Pipeline Progress and 2017 Operating Results
Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018 Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018 Novel ADC Pipeline Continues to Advance with
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its 2017 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A. Arbuckle to its Board of Directors. Mr.
View HTML
Toggle Summary ImmunoGen Announces First Patient Dosed in Phase 1 Study of IMGN632 for Hematological Malignancies
Second ADC Using ImmunoGen’s Novel DNA-Alkylating Payloads to Enter the Clinic WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has
View HTML